Elamipretide vs PT-141
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | PT-141 |
|---|---|---|
| Category | Muscle & Performance | Performance |
| Full Name | Elamipretide (MTP-131, SS-31) | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 639.8 Da | 1,025.2 Da |
| Half-Life | 1-4 hours | ~2.7 hours |
| Amino Acids | 4 | 7 |
| Typical Dose | 0.01-0.25 mg/kg/day | 1.75 mg |
| Route | Subcutaneous/Intravenous | SC |
| Purity | ≥98% | — |
| Studies Count | 120 | 178 |
| Research Status | Clinical | FDA Approved |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.